CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
by ulrich quistgaard, translated by daniel pedersen
It now appears that fraudulent clinical trials by Indian contract research organization (CRO) Synchron Research Service will have an impact on the European market for generic medicines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA publishes new plan to support antibiotic development
For subscribers
Indian generic drugmaker settles lawsuit with Leo Pharma
For subscribers
